

DR REDDYS LABORATORIES LTD

Form 6-K

December 05, 2007

**FORM 6-K**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**  
**Report of Foreign Private Issuer**  
**Pursuant to Rule 13a-16 or 15d-16**  
**of the Securities Exchange Act of 1934**  
**For the Month of October 2007**  
**Commission File Number 1-15182**  
**DR. REDDY S LABORATORIES LIMITED**  
(Name of Registrant)  
**7-1-27, Ameerpet**  
**Hyderabad, Andhra Pradesh 500 016, India**  
**+91-40-23731946**

(Address of Principal Executive Offices)

Indicate by check mark whether registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ;

**Note:** Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

**Note:** Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's home country), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If Yes is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b):

Not applicable.

**Table of Contents**

- (1) Press Release, Dr. Reddy's to release Q2 FY08 results on October 24, 2007; Earnings call slated for October 24, 6.30 PM IST/9.00 AM EST, October 18, 2007.
- (2) Press Release, Dr. Reddy's Q2 FY08 revenue at Rs 12,670 million; Net income at Rs 2,672, October 24, 2007.

**Press Release**

Dr. Reddy s Laboratories Ltd.  
7-1-27 Ameerpet  
Hyderabad 500 016 India

Tel: 91 40 373 1946  
Fax: 91 40 373 1955

[www.drreddys.com](http://www.drreddys.com)

**Hyderabad, India, October 18, 2007**

**Dr. Reddy s to release Q2 FY08 results on October 24, 2007;**

**Earnings call slated for October 24, 6.30 PM IST/9.00 AM EST**

**Hyderabad, India, 18th October 2007:** Dr. Reddy s Laboratories (NYSE: RDY) will announce results for the second quarter ended September 30, 2007 on Wednesday, October 24, 2007 after the Board Meeting. The results will be available on the Company s website [www.drreddys.com](http://www.drreddys.com)

**Summary of Events**

<b>Event</b>	<b>Date and Time (IST)</b>	<b>Medium</b>
<b>Release of financial results</b>	<b>October 24, after the Board Meeting</b>	<b>Email, Media, Company website, Businesswire</b>
<b>Earnings Call</b>	<b>October 24, 6.30 PM IST / 9.00 AM EST</b>	<b>Hosted by the Company (Details below)</b>
<b>Webcast of Earnings Call</b>	<b>October 24, 6.30 PM IST / 9.00 AM EST through October 31, 2007.</b>	<b>URL available on Company s website, <a href="http://www.drreddys.com">www.drreddys.com</a></b>
<b>Transcripts of the Earnings call</b>	<b>Available on the Company s website</b>	<b>URL available on Company s website, <a href="http://www.drreddys.com">www.drreddys.com</a></b>

**Earnings Call**

Following the release, the management of the Company will host an earnings call to discuss the Company s financial performance.

<b>Date</b>	<b>Timing</b>	<b>Dial-in number</b>
<b>October 24, 2007</b>	<b>India 6.30 PM US EST 9.00 AM</b>	<b>Participants from India 022.2781.3043 Stand by 022.67763743</b>
		<b>Participants from: US - TOLL FREE: 877 209 0463 US/International Toll Number : +1 706 643 0243 Conference ID: 19865215#</b>
		<b>Singapore Toll Free Number: 800 101 1350</b>



No password/pin number is necessary to dial in to any of the other calls. As participation in the call is limited, early registration is encouraged. The operator will provide instructions on asking questions before and during the call.

**Audio Webcast**

The audio webcast of the earnings call will be available to all interested parties at [www.drreddys.com](http://www.drreddys.com). Please visit the web site at least fifteen minutes ahead of the scheduled start time to register and to download and install any necessary audio software. Participants in the webcast can listen to the proceedings, but will not be able to ask questions. The replay will be available 2 hours after the earnings call, through October 31, 2007.

**Transcript**

The transcript of the earnings call will also be available on the Company's website.

**About Dr Reddy's**

Established in 1984, Dr. Reddy's (NYSE: RDY) is a vertically integrated, global pharmaceutical company with proven research capabilities and presence across the pharmaceutical value chain. The company manufactures Active Pharmaceutical Ingredients and Finished Dosage forms and market them globally, with a focus on United States, Europe, India and Russia. In addition, the drug discovery arm of the company conducts basic research in the areas of diabetes, cardiovascular, inflammation and bacterial infection. Website: <http://www.drreddys.com>

**Contact**

For further information please contact:

Investor Relations: Nikhil Shah ([nikhilshah@drreddys.com](mailto:nikhilshah@drreddys.com)) or on +91-40-66511532

**Press Release**

Dr. Reddy s Laboratories Ltd.  
7-1-27 Ameerpet  
Hyderabad 500 016 India

Tel: 91 40 373 1946  
Fax: 91 40 373 1955

[www.drreddys.com](http://www.drreddys.com)

**Hyderabad, India, October 24, 2007**

**Dr. Reddy s Q2 FY08 revenue at Rs 12,670 million;**

**Net income at Rs 2,672 million;**

**Hyderabad, India, October 24, 2007:** Dr. Reddy s Laboratories Ltd. (NYSE: RDY) today announced its unaudited financial results for the quarter ended September 30, 2007.

***Growth in revenues at 20% in dollar terms excluding the upsides from authorized generics in Q2 FY07 of Rs 7.8 billion (\$196 mn)***

***Q2 FY08 Revenue at Rs 12.7 billion (\$319 mn) as against Rs 20 billion (\$504 mn) in Q2 FY07***

***Q2 FY08 PBT at Rs 1,422 million (\$36 mn) as against Rs 3,531 million (\$89 mn) in Q2 FY07***

***Q2 FY08 PAT at Rs 2,672 million (\$67 mn) as against Rs 2,798 million (\$70 mn) in Q2 FY07***

**Reversal of deferred tax liability related to betapharm results in a benefit of Rs 1.5 billion (\$36.5 mn) in Q2 FY08**

**Q2 FY08 Key highlights**

Revenues at Rs 12.7 billion (\$319 mn) in Q2 FY08 as against Rs 20 billion (\$504 mn) in Q2 FY07, representing a decrease of 37%

- o Revenues increase by 4% (in rupee terms) in Q2 FY08 after excluding the upsides from authorized generics in Q2 FY07.

Revenues in India (finished dosage) increase by 9% to Rs. 2 billion (\$52 mn) in Q2 FY08 from Rs. 1.9 billion (\$48 mn) in Q2 FY07 driven by growth in key brands and new product launches.

Revenues in Russia (finished dosage) increase by 25% to Rs. 980 million (\$25 mn) in Q2 FY08 from Rs. 783 million (\$20 mn) in Q2 FY07 driven by growth in key brands as well as contribution from new product launches in FY07.

Revenues from North America (finished dosages) increase by 63% to Rs 2 billion (\$52 mn) excluding the benefit of upsides from authorized generics in Q2 FY07 of Rs 7.8 billion. Combined revenues from fexofenadine and finasteride at Rs 1.2 billion (\$31 mn) during Q2 FY08.

Revenues from Germany (betapharm) at Rs. 1.9 billion (\$47 mn) in Q2 FY08 as compared to Rs. 2.6 billion (\$ 64 mn) in Q2 FY07. The decline in revenues is on account of ongoing supply constraints as well as rupee appreciation against the Euro.

- o As per INSIGHT August 2007, betapharm recorded a combined 28% growth in pharmacy volumes for July and August.

- o Around 20 products transferred out of Salutas including 6 to India; On track to transfer the key products out of Salutas by end of FY08

Revenues in the API business increase by 11.5% to Rs 3.2 billion (\$82 mn) in Q2 FY08 from Rs 2.9 billion (\$73 mn) in Q2 FY07 primarily driven by growth across key markets.



Revenues from organic segment of custom pharmaceuticals services business increase by 125% to Rs 528 million (\$13 mn) in Q2 FY08 from Rs 234 million (\$6 mn) in Q2 FY07.

*All figures in millions, except EPS*

*All dollar figures based on convenience translation rate of 1USD = Rs 39.75*

6

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

DR. REDDY S LABORATORIES LIMITED  
(Registrant)

By: /s/ V. Viswanath

Date: December 5, 2007

Name: V. Viswanath  
Title: Company Secretary

7

"BORDER-BOTTOM: #000000 2pt double">2,573 \$2,617 \$2,633 \$2,650 \$2,628 Distributions paid on common stock \$2,591 \$2,602 \$2,603 \$2,603 \$2,603 Distributions paid on common stock per share 0.375 0.375 0.375 0.375 0.375 Payout percentage for period(4) 100.7% 99.4% 98.9% 98.2% 99.1% Net realized gain on investments and interest rate swaps, for the period 1,325 1,764 1,251 506 808 Total assets, end of period 188,170 183,009 193,637 204,102 212,268 Average total assets during period(5) 181,412 188,261 190,519 200,243 207,351 Leverage (long-term debt obligations and short-term borrowings)(6) 31,100 32,500 32,650 32,700 32,300 Leverage as a percent of total assets 16.5% 17.8% 16.9% 16.0% 15.2% Net unrealized appreciation, end of period 21,387 18,252 28,090 39,346 48,673 Net assets, end of period 152,231 149,567 159,362 169,874 178,732 Average net assets during period(7) 149,001 154,058 156,594 167,033 172,182 Net asset value per common share 21.96 21.55 22.96 24.47 25.75 Market value per common share 20.20 21.05 22.38 23.06 24.86 Shares outstanding 6,931,555 6,940,986 6,940,986 6,940,986 6,940,986 Selected Operating Ratios(8) As a Percent of Average Total Assets Total distributions received from investments 7.53% 7.25% 7.22% 6.93% 6.75% Operating expenses before leverage costs 1.07% 1.04% 1.05% 1.01% 1.03% Distributable cash flow before leverage costs 6.46% 6.21% 6.17% 5.92% 5.72% As a Percent of Average Net Assets Distributable cash flow(3) 7.00% 6.74% 6.67% 6.36% 6.19%

- (1) Q1 is the period from December through February. Q2 is the period from March through May. Q3 is the period from June through August. Q4 is the period from September through November.
- (2) Leverage costs include interest expense, interest rate swap expenses and other leverage expenses.
- (3) "Net investment income" on the Statement of Operations is adjusted as follows to reconcile to Distributable Cash Flow (DCF): increased by the return of capital on MLP distributions, the value of paid-in-kind distributions, amortization of debt issuance costs and the change in methodology for calculating amortization of premiums or discounts; and decreased by realized and unrealized gains (losses) on interest rate swap settlements.
- (4) Distributions paid as a percentage of Distributable Cash Flow.
- (5) Computed by averaging month-end values within each period.
- (6) The balance on the short-term credit facility was \$12,300,000 as of February 28, 2011.
- (7) Computed by averaging daily values within each period.
- (8) Annualized for periods less than one full year. Operating ratios contained in our Financial Highlights are based on average net assets.

2 Tortoise Power and Energy Infrastructure Fund, Inc.

---

---

## Management's Discussion (Unaudited)

The information contained in this section should be read in conjunction with our Financial Statements and the Notes thereto. In addition, this report contains certain forward-looking statements. These statements include the plans and objectives of management for future operations and financial objectives and can be identified by the use of forward-looking terminology such as "may," "will," "expect," "intend," "anticipate," "estimate," or "continue" or the negative thereof or other variations thereon or comparable terminology. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. Certain factors that could cause actual results and conditions to differ materially from those projected in these forward-looking statements are set forth in the "Risk Factors" section of our public filings with the SEC.

### Overview

Tortoise Power and Energy Infrastructure Fund, Inc.'s ("TPZ") primary investment objective is to provide a high level of current income, with a secondary objective of capital appreciation. We seek to provide our stockholders a vehicle to invest in a portfolio consisting primarily of securities issued by power and energy infrastructure companies. Power infrastructure operations use asset systems to provide electric power generation (including renewable energy), transmission and distribution. Energy infrastructure operations use a network of pipeline assets to transport, store, gather and/or process crude oil, refined petroleum products (including biodiesel and ethanol), natural gas or natural gas liquids. We believe the power and energy infrastructure sectors provide stable and defensive characteristics throughout economic cycles. A majority of the investments are in fixed income securities with the remainder invested in equities which provide growth potential.

TPZ is a registered non-diversified, closed-end management investment company under the Investment Company Act of 1940, as amended (the "1940 Act"), and expects to qualify as a regulated investment company ("RIC") under the U.S. Internal Revenue Code of 1986, as amended (the "Code"). Tortoise Capital Advisors, L.L.C. (the "Adviser") serves as investment adviser.

### Company Update

Market values of both our debt and equity investments ended the 1st quarter 2011 above their levels at November 30, 2010, contributing to an increase of \$8.2 million in total assets. Interest and distributions received from our investments declined slightly during the quarter while the increase in total assets during the quarter resulted in increased asset-based expenses. Total leverage decreased as a percent of total assets and we maintained our monthly distribution of \$0.125 per share. Additional information on the results of our operations is discussed in more detail below.

### Critical Accounting Policies

The financial statements are based on the selection and application of critical accounting policies, which require management to make significant estimates and assumptions. Critical accounting policies are those that are both important to the presentation of our financial condition and results of operations and require management's most difficult, complex, or subjective judgments. Our critical accounting policies are those applicable to the valuation of investments and certain revenue recognition matters as discussed in Note 2 in the Notes to Financial Statements.

### Determining Distributions to Stockholders

Unlike most RIC's which pay distributions based upon income, we pay monthly distributions based upon our distributable cash flow ("DCF"). Our Board of Directors reviews the distribution rate quarterly, and may adjust the monthly distributions throughout the year.

### Determining DCF

DCF is simply income from investments less expenses. Income from investments includes the accrued interest from corporate bonds, cash distributions and paid-in-kind distributions from MLPs and related companies and dividends earned from short-term investments. The total expenses include current or anticipated operating expenses and leverage costs. Each are summarized for you in the table on page 2 and are discussed in more detail below.

The Key Financial Data table discloses the calculation of DCF and should be read in conjunction with this discussion. The difference between income from investments in the DCF calculation and total investment income as reported in the Statement of Operations, is reconciled as follows: (1) GAAP recognizes distribution income from MLPs and common stock on their ex-dates, whereas the DCF calculation reflects distribution income on their pay dates; (2) GAAP recognizes that a significant portion of the cash distributions received from MLPs are

## Edgar Filing: DR REDDYS LABORATORIES LTD - Form 6-K

characterized as a return of capital and therefore excluded from investment income, whereas the DCF calculation includes the return of capital; (3) income from investments in the DCF calculation includes the value of dividends paid-in-kind (additional stock or units), whereas such amounts are not included as income for GAAP purposes; and (4) amortization of premium or discount for all securities is calculated using the yield to worst methodology for GAAP purposes while yield to call is used in calculating amortization for long-dated hybrid securities in the DCF calculation. The treatment of expenses in the DCF calculation also differs from what is reported in the Statement of Operations. In addition to the total operating expenses, including expense reimbursement, as disclosed in the Statement of Operations, the DCF calculation reflects interest expense and realized and unrealized gains (losses) on interest rate swap settlements as leverage costs. A reconciliation of Net Investment Income to DCF is included below.

### Income from Investments

We seek to achieve our investment objectives by investing in income-producing fixed income and equity securities of companies that we believe offer attractive distribution rates. We evaluate each holding based upon its contribution to our investment income and its risk relative to other potential investments.

Total income from investments for the 1st quarter 2011 was approximately \$3.5 million, a slight decrease as compared to 4th quarter 2010. This decrease is due to an exchange during the quarter from a higher yielding debt investment to lower yielding investments, offset by distribution increases from our MLPs.

### Expenses

We incur two types of expenses: (1) operating expenses, consisting primarily of the advisory fee, and (2) leverage costs. On a percentage basis, operating expenses before leverage costs were an annualized 1.03 percent of average total assets for 1st quarter 2011 as compared to 1.01 percent for the 4th quarter 2010 and 1.07 percent for 1st quarter 2010. Advisory fees for 1st quarter 2011 increased 1.0 percent from 4th quarter 2010 as a result of increased market values and average managed assets during the quarter.

While the contractual advisory fee is 0.95 percent of average monthly managed assets, the Adviser has agreed to waive an amount equal to 0.15, 0.15 and 0.10 percent of average monthly managed assets for the calendar years 2010, 2011 and 2012, respectively.

Leverage costs consist of two major components: (1) the direct interest expense, which will vary from period to period, as our senior notes and revolving credit facility have variable rates of interest, and (2) the realized and unrealized gain or loss on our interest rate swap settlements. Detailed information on our senior notes and revolving credit facility is included in the Liquidity and Capital Resources section below.

## Management's Discussion (Unaudited)

(Continued)

As indicated in Note 10 of our Notes to Financial Statements, we have entered into \$27 million notional amount of interest rate swap contracts with Wells Fargo Bank in an attempt to reduce a portion of the interest rate risk arising from our leveraged capital structure. TPZ has agreed to pay Wells Fargo Bank a fixed rate while receiving a floating rate based upon the 1-month or 3-month U.S. Dollar London Interbank Offered Rate ("LIBOR"). The spread between the fixed swap rate and LIBOR is reflected in our Statement of Operations as a realized or unrealized gain when LIBOR exceeds the fixed rate (Wells Fargo Bank pays TPZ the net difference) or a realized or unrealized loss when the fixed rate exceeds LIBOR (TPZ pays Wells Fargo Bank the net difference). The interest rate swap contracts have a weighted average fixed rate of 2.13 percent and weighted average remaining maturity of approximately 2.6 years at February 28, 2011. This swap arrangement effectively fixes the cost on approximately 84 percent of our outstanding leverage as of February 28, 2011 over the remaining swap period.

Total leverage costs for DCF purposes were approximately \$297,000 for the 1st quarter 2011, a decrease of approximately 2 percent as compared to 4th quarter 2010 due primarily to reduced utilization of our credit facility during the 1st quarter 2011. This includes interest expense on our senior notes and bank credit facility and accrued swap settlement costs of approximately \$124,000. The average annualized total cost of leverage (total leverage costs divided by average outstanding leverage) was 3.78 percent for 1st quarter 2011.

## Distributable Cash Flow

For 1st quarter 2011, our DCF was approximately \$2.63 million, a decrease of 0.8 percent as compared to 4th quarter 2010. This decrease is the net result of the change in distributions and expenses as outlined above. On November 8, 2010, we declared monthly distributions for the 2011 1st fiscal quarter of \$0.125 per share. This is unchanged as compared to 4th quarter 2010.

Our dividend payout ratio as a percentage of DCF increased from 98.2 percent during 4th quarter 2010 to 99.1 percent during 1st quarter 2011. A payout of less than 100 percent of DCF provides cushion for on-going management of the portfolio, changes in leverage costs and other expenses. An on-going payout ratio in excess of 100 percent will, over time, erode the earning power of a portfolio and may lead to lower distributions or portfolio managers taking on more risk than they otherwise would.

Net investment income on the Statement of Operations is adjusted as follows to reconcile to DCF for the 1st quarter 2011 (in thousands):

	1st Qtr 2011
Net Investment Income	\$ 1,326
Adjustments to reconcile to DCF:	
Dividends paid in stock	604
Return of capital on distributions	755
Amortization of debt issuance costs	9
Interest rate swap expenses	(124)
Change in amortization methodology	58
DCF	\$ 2,628

## Liquidity and Capital Resources

We had total assets of \$212.3 million at quarter-end. Our total assets reflect the value of our investments, which are itemized in the Schedule of Investments. It also reflects cash, interest and receivables and any expenses that may have been prepaid. During the 1st quarter 2011, total assets increased from \$204.1 million to \$212.3 million, an increase of \$8.2 million which was primarily the result of net realized and unrealized gains on investments during the quarter (excluding return of capital on distributions reflected during the quarter) offset by a small reduction in outstanding borrowings on our bank credit facility.

Total leverage outstanding at February 28, 2011 of \$32.3 million is comprised of \$20 million floating rate senior notes and \$12.3 million outstanding on our bank credit facility. Through the utilization of our interest rate swaps, we have essentially fixed the rate on approximately 84 percent of our leverage with the remaining 16 percent floating based upon short-term LIBOR. Total leverage represented 15.2 percent of total assets. We've allowed leverage as a percent of total assets to decrease as market values increased rather than maintain leverage to total assets at

## Edgar Filing: DR REDDYS LABORATORIES LTD - Form 6-K

the long-term target level of 20 percent of total assets. This allows the opportunity to add leverage when compelling investment opportunities arise. Temporary increases to up to 25 percent of our total assets may be permitted, provided that such leverage is consistent with the limits set forth in the 1940 Act, and that such leverage is expected to be reduced over time in an orderly fashion to reach our long-term target. Our leverage ratio is impacted by increases or decreases in investment values, issuance of equity and/or the sale of securities where proceeds are used to reduce leverage.

We have used leverage to acquire investments consistent with our investment philosophy. The terms of our leverage are governed by regulatory and contractual asset coverage requirements that arise from the use of leverage. Additional information on our leverage and asset coverage requirements is discussed in Note 9 in the Notes to Financial Statements. Our coverage ratio is updated each week on our Web site at [www.tortoiseadvisors.com](http://www.tortoiseadvisors.com).

### Taxation of our Distributions

We expect that distributions paid on common shares will generally consist of: (i) investment company taxable income (which includes, among other items, taxable interest and the excess of any short-term capital gains over net long-term capital losses); (ii) long-term capital gain (net gain from the sale of a capital asset held longer than 12 months over net short-term capital losses) and (iii) return of capital.

We may distribute additional capital gains in the last fiscal quarter if necessary to meet minimum distribution requirements and thus avoid being subject to excise taxes. If, however, we elect to retain any capital gains, we will be subject to U.S. capital gains taxes. The payment of those taxes will flow-through to stockholders as a tax credit to apply against their U.S. income tax payable on the deemed distribution of the retained capital gain.

For tax purposes, distributions paid to common stockholders for the calendar year ended December 31, 2010 were approximately 88 percent ordinary income (none of which is qualified dividend income), 6 percent long-term capital gain and 6 percent return of capital. A holder of our common stock would reduce their costs basis for income tax purposes by approximately 6 percent of the total distributions they received in 2010. This information is reported to stockholders on Form 1099-DIV and is available on our Web site at [www.tortoiseadvisors.com](http://www.tortoiseadvisors.com).

## Schedule of Investments

February 28, 2011

(Unaudited)

	Principal Amount/Shares	Fair Value
Corporate Bonds — 65.1%(1)		
Crude/Refined Products Pipelines — 1.9%(1)		
Canada — 1.9%(1)		
Gibson Energy ULC/GEP Midstream Finance Corp., 10.000%, 01/15/2018	\$ 3,250,000	\$ 3,396,250
Natural Gas/Natural Gas Liquids Pipelines — 18.5%(1)		
Canada — 3.4%(1)		
TransCanada Pipelines Limited, 6.350%, 05/15/2067	6,000,000	6,098,358
United States — 15.1%(1)		
El Paso Corp., 6.500%, 09/15/2020(2)	4,000,000	4,258,784
El Paso Corp., 7.000%, 06/15/2017	1,000,000	1,117,219
Florida Gas Transmission Co., LLC, 5.450%, 07/15/2020(2)	1,500,000	1,571,618
Midcontinent Express Pipeline LLC, 6.700%, 09/15/2019(2)	6,000,000	6,631,176
NGPL PipeCo LLC, 7.119%, 12/15/2017(2)	4,000,000	4,497,776
Southern Star Central Corp., 6.750%, 03/01/2016	2,745,000	2,799,900
Southern Star Central Gas Pipeline, Inc., 6.000%, 06/01/2016(2)	2,000,000	2,161,278
Southern Union Co., 7.600%, 02/01/2024	3,500,000	3,860,440
		32,996,549
Natural Gas Gathering/Processing — 5.3%(1)		
United States — 5.3%(1)		
DCP Midstream LLC, 9.750%, 03/15/2019(2)	4,000,000	5,178,344
Enogex LLC, 6.250%, 03/15/2020(2)	4,000,000	4,295,432
		9,473,776
Oil and Gas Exploration and Production — 5.3%(1)		
United States — 5.3%(1)		
Chesapeake Energy Corp., 7.250%, 12/15/2018	2,000,000	2,205,000
Encore Acquisition Co.,		

Edgar Filing: DR REDDYS LABORATORIES LTD - Form 6-K

9.500%, 05/01/2016	1,500,000	1,695,000
Newfield Exploration Co.,		
7.125%, 05/15/2018	1,000,000	1,067,500
Pioneer Natural Resources Co.,		
6.875%, 05/01/2018	1,000,000	1,085,681
Plains Exploration & Production Co.,		
10.000%, 03/01/2016	3,000,000	3,405,000
		9,458,181
Oilfield Services — 2.0%(1)		
United States — 2.0%(1)		
Pride International, Inc.,		
8.500%, 06/15/2019	3,000,000	3,660,000
Power/Utility — 30.2%(1)		
United States — 30.2%(1)		
Ameren Illinois Power Co.,		
9.750%, 11/15/2018	2,000,000	2,576,394
CenterPoint Energy, Inc.,		
6.500%, 05/01/2018	4,000,000	4,507,244
CMS Energy Corp.,		
8.750%, 06/15/2019	4,185,000	5,013,584
Dominion Resources, Inc.,		
8.375%, 06/15/2064	183,000	5,279,550
FPL Group Capital, Inc.,		
6.650%, 06/15/2067	1,029,000	1,023,855
Integrus Energy Group, Inc.,		
6.110%, 12/01/2066	3,750,000	3,646,875
IPALCO Enterprises, Inc.,		
7.250%, 04/01/2016(2)	4,000,000	4,340,000
North American Energy Alliance LLC,		
10.875%, 06/01/2016(2)	2,800,000	3,164,000
NRG Energy, Inc.,		
8.500%, 06/15/2019	6,000,000	6,390,000
PPL Capital Funding, Inc.,		
6.700%, 03/30/2067	6,000,000	5,895,000
Sierra Pacific Resources,		
6.750%, 08/15/2017	3,000,000	3,073,437
Source Gas, LLC,		
5.900%, 04/01/2017(2)	5,770,000	5,701,210
Wisconsin Energy Corp.,		
6.250%, 05/15/2067	3,450,000	3,445,687
		54,056,836
Refining — 1.9%(1)		
United States — 1.9%(1)		
Holly Corp.,		
9.875%, 06/15/2017	3,000,000	3,337,500
Total Corporate Bonds (Cost \$107,123,432)		116,379,092

See accompanying Notes to Financial Statements.





## Schedule of Investments (Continued)

February 28, 2011

(Unaudited)

	Shares	Fair Value
Master Limited Partnerships and Related Companies — 52.2%(1)		
Crude/Refined Products Pipelines — 26.4%(1)		
United States — 26.4%(1)		
Buckeye Partners, L.P.	25,300	\$ 1,639,946
Enbridge Energy Management, L.L.C.(3)(4)	284,098	18,994,802
Holly Energy Partners, L.P.	27,549	1,643,298
Kinder Morgan Management, LLC(3)	275,496	18,075,293
Magellan Midstream Partners, L.P.	19,400	1,172,536
NuStar Energy L.P.	32,600	2,286,890
Plains All American Pipeline, L.P.	16,500	1,080,255
Sunoco Logistics Partners L.P.	26,481	2,343,304
		47,236,324
Natural Gas/Natural Gas Liquids Pipelines — 13.2%(1)		
United States — 13.2%(1)		
Boardwalk Pipeline Partners, LP	120,000	3,985,200
Duncan Energy Partners L.P.	101,700	4,142,241
Energy Transfer Equity, L.P.	27,809	1,117,644
Energy Transfer Partners, L.P.	107,700	5,905,191
Enterprise Products Partners L.P.	33,600	1,464,960
Niska Gas Storage Partners LLC	6,866	139,036
ONEOK Partners, L.P.	66,600	5,537,790
Williams Partners, L.P.	23,932	1,241,113
		23,533,175
Natural Gas Gathering/Processing — 8.0%(1)		
United States — 8.0%(1)		
Copano Energy, L.L.C.	93,200	3,374,772
DCP Midstream Partners, LP	85,200	3,600,552
MarkWest Energy Partners, L.P.	56,700	2,545,830
Regency Energy Partners, L.P.	10,600	294,362
Targa Resources Partners L.P.	132,417	4,535,282
		14,350,798
Propane Distribution — 4.6%(1)		
United States — 4.6%(1)		
Inergy, L.P.	197,500	8,192,300
Total Master Limited Partnerships and Related Companies (Cost \$53,211,808)		93,312,597
Short-Term Investment — 0.0%(1)		

Edgar Filing: DR REDDYS LABORATORIES LTD - Form 6-K

United States Investment Company — 0.0(1)		
Fidelity Institutional Government Portfolio —		
Class I, 0.01%(5) (Cost \$37,166)	37,166	37,166
Total Investments — 117.3%(1)		
(Cost \$160,372,406)		209,728,855
Long-Term Debt Obligations — (11.2%)(1)		
		(20,000,000)
Interest Rate Swap Contracts — (0.4%)(1)		
\$27,000,000 notional — Unrealized Depreciation(6)		
		(683,459)
Other Assets and Liabilities — (5.7%)(1)		
		(10,312,985)
Total Net Assets Applicable to		
Common Stockholders — 100.0%(1)	\$	178,732,411

(1) Calculated as a percentage of net assets applicable to common stockholders.

(2) Restricted securities have been fair valued in accordance with procedures approved by the Board of Directors and have a total fair value of \$41,799,618, which represents 23.4% of net assets. See Note 7 to the financial statements for further disclosure.

(3) Security distributions are paid-in-kind.

(4) A portion of the security is segregated as collateral for the unrealized depreciation of interest rate swap contracts.

(5) Rate indicated is the current yield as of February 28, 2011.

(6) See Note 10 of the financial statements for further disclosure.

See accompanying Notes to Financial Statements.

6 Tortoise Power and Energy Infrastructure Fund, Inc.

## Statement of Assets & Liabilities

February 28, 2011

(Unaudited)

Assets	
Investments at fair value (cost \$160,372,406)	\$ 209,728,855
Receivable for Adviser expense reimbursement	49,848
Interest and dividend receivable	2,261,699
Prepaid expenses and other assets	227,586
Total assets	212,267,988

Liabilities	
Payable to Adviser	315,706
Accrued expenses and other liabilities	236,412
Unrealized depreciation of interest rate swap contracts	683,459
Short-term borrowings	12,300,000
Long-term debt obligations	20,000,000
Total liabilities	33,535,577
Net assets applicable to common stockholders	\$ 178,732,411

### Net Assets Applicable to Common Stockholders Consist of:

Capital stock, \$0.001 par value; 6,940,986 shares issued and outstanding (100,000,000 shares authorized)	\$ 6,941
Additional paid-in capital	130,052,419
Undistributed net investment income	—
Undistributed net realized gain	—
Net unrealized appreciation of investments and interest rate swap contracts	48,673,051
Net assets applicable to common stockholders	\$ 178,732,411
Net Asset Value per common share outstanding (net assets applicable to common stock, divided by common shares outstanding)	\$ 25.75

## Statement of Operations

Period from December 1, 2010 through February 28, 2011

(Unaudited)

Investment Income	
Distributions from master limited partnerships	\$ 839,469
Less return of capital on distributions	(755,006)
Net distributions from master limited partnerships	84,463
Interest from corporate bonds	1,951,430
Dividends from money market mutual funds	36
Total Investment Income	2,035,929
Operating Expenses	
Advisory fees	477,931
Professional fees	42,518

Edgar Filing: DR REDDYS LABORATORIES LTD - Form 6-K

Administrator fees	20,124
Stockholder communication expenses	17,631
Directors' fees	16,792
Registration fees	6,109
Fund accounting fees	5,918
Franchise fees	4,931
Stock transfer agent fees	3,181
Custodian fees and expenses	2,604
Other operating expenses	6,159
Total Operating Expenses	603,898
Leverage Expenses	
Interest expense	155,966
Amortization of debt issuance costs	9,314
Other leverage expenses	16,243
Total Leverage Expenses	181,523
Total Expenses	785,421
Less expense reimbursement by Adviser	(75,463)
Net Expenses	709,958
Net Investment Income	1,325,971
Realized and Unrealized Gain on	
Investments and Interest Rate Swaps	
Net realized gain on investments	934,262
Net realized loss on interest rate swap settlements	(126,052)
Net realized gain on investments and interest rate swaps	808,210
Net unrealized appreciation of investments	9,025,687
Net unrealized appreciation of interest rate swap contracts	301,565
Net unrealized appreciation of investments and interest rate swap contracts	9,327,252
Net Realized and Unrealized Gain on Investments and Interest Rate Swaps	10,135,462
Net Increase in Net Assets Applicable to Common Stockholders Resulting from Operations	\$ 11,461,433

See accompanying Notes to Financial Statements.

## Statement of Changes in Net Assets

	Period from December 1, 2010 through February 28, 2011 (Unaudited)	Year Ended November 30, 2010
<b>Operations</b>		
Net investment income	\$ 1,325,971	\$ 5,065,947
Net realized gain on investments and interest rate swaps	808,210	4,846,309
Net unrealized appreciation of investments and interest rate swap contracts	9,327,252	27,704,408
Net increase in net assets applicable to common stockholders resulting from operations	11,461,433	37,616,664
<b>Distributions to Common Stockholders</b>		
Net investment income	(1,679,736)	(4,333,154)
Net realized gain	(808,210)	(5,367,201)
Return of capital	(114,924)	(698,239)
Total distributions to common stockholders	(2,602,870)	(10,398,594)
<b>Capital Stock Transactions</b>		
Issuance of 42,505 common shares from reinvestment of distributions to stockholders	—	866,404
Net increase in net assets applicable to common stockholders from capital stock transactions	—	866,404
Total increase in net assets applicable to common stockholders	8,858,563	28,084,474
<b>Net Assets</b>		
Beginning of period	169,873,848	141,789,374
End of period	\$ 178,732,411	\$ 169,873,848
Undistributed net investment income, end of period	\$ —	\$ 353,765

See accompanying Notes to Financial Statements.

## Statement of Cash Flows

Period from December 1, 2010 through February 28, 2011

(Unaudited)

<b>Cash Flows From Operating Activities</b>		
Distributions received from master limited partnerships	\$	839,469
Interest and dividend income received		1,907,273
Purchases of long-term investments		(4,279,590)
Proceeds from sales of long-term investments		5,293,689
Proceeds from sales of short-term investments, net		20,702
Payments on interest rate swaps, net		(126,052)
Interest received on securities sold, net		41,362
Interest expense paid		(159,331)
Other leverage expenses paid		(8,400)
Income taxes paid		(1,900)
Operating expenses paid		(524,352)
Net cash provided by operating activities		3,002,870
<b>Cash Flows From Financing Activities</b>		
Advances from revolving line of credit		6,500,000
Repayments on revolving line of credit		(6,900,000)
Distributions paid to common stockholders		(2,602,870)
Net cash used in financing activities		(3,002,870)
Net change in cash		—
Cash — beginning of period		—
Cash — end of period	\$	—
<b>Reconciliation of net increase in net assets applicable to common stockholders resulting from operations to net cash provided by operating activities</b>		
Net increase in net assets applicable to common stockholders resulting from operations	\$	11,461,433
Adjustments to reconcile net increase in net assets applicable to common stockholders resulting from operations to net cash provided by operating activities:		
Purchases of long-term investments		(4,279,590)
Return of capital on distributions received		755,006
Proceeds from sales of long-term investments		5,293,689
Proceeds from sales of short-term investments, net		20,702
Net unrealized appreciation of investments and interest rate swap contracts		(9,327,252)
Net realized gain on investments		(934,262)
Amortization of market premium, net		67,297
Amortization of debt issuance costs		9,314
Changes in operating assets and liabilities:		
Increase in interest and dividend receivable		(70,129)
Increase in prepaid expenses and other assets		(3,582)
Decrease in current foreign tax liability		(1,660)
Decrease in payable to Adviser, net of		

Edgar Filing: DR REDDYS LABORATORIES LTD - Form 6-K

expense reimbursement		(4,380)
Increase in accrued expenses and other liabilities		16,284
Total adjustments		(8,458,563)
Net cash provided by operating activities	\$	3,002,870

See accompanying Notes to Financial Statements.

2011 1st Quarter Report 9

---



## Financial Highlights

	Period from December 1, 2010 through February 28, 2011 (Unaudited)	Year Ended November 30, 2010	Period from July 31, 2009(1) through November 30, 2009
<b>Per Common Share Data(2)</b>			
Net Asset Value, beginning of period	\$ 24.47	\$ 20.55	\$ —
Public offering price	—	—	20.00
<b>Income from Investment Operations</b>			
Net investment income(3)	0.19	0.73	0.17
Net realized and unrealized gains on investments and interest rate swap contracts(3)	1.47	4.69	1.70
Total income from investment operations	1.66	5.42	1.87
<b>Distributions to Common Stockholders</b>			
Net investment income	(0.24)	(0.63)	(0.16)
Net realized gain	(0.12)	(0.77)	—
Return of capital	(0.02)	(0.10)	(0.22)
Total distributions to common stockholders	(0.38)	(1.50)	(0.38)
Underwriting discounts and offering costs on issuance of common stock	—	—	(0.94)
Net Asset Value, end of period	\$ 25.75	\$ 24.47	\$ 20.55
Per common share market value, end of period	\$ 24.86	\$ 23.06	\$ 19.18
Total Investment Return Based on Market Value(4)	9.46%	28.83%	(2.17)%
Total Investment Return Based on Net Asset Value(5)	6.84%	27.60%	4.82%
<b>Supplemental Data and Ratios</b>			
Net assets applicable to common stockholders, end of period (000's)	\$ 178,732	\$ 169,874	\$ 141,789
Average net assets (000's)	\$ 172,182	\$ 156,685	\$ 134,521
<b>Ratio of Expenses to Average Net Assets(6)</b>			
Advisory fees	1.12%	1.15%	1.06%
Other operating expenses	0.30	0.30	0.47
Expense reimbursement	(0.18)	(0.18)	(0.17)
Subtotal	1.24	1.27	1.36
Leverage expenses	0.43	0.52	0.43
Current foreign tax expense(7)	—	0.00	—
Total expenses	1.67%	1.79%	1.79%
Ratio of net investment income to average net assets before expense reimbursement(6)	2.94%	3.05%	2.38%
Ratio of net investment income to average net assets after expense reimbursement(6)	3.12%	3.23%	2.55%
Portfolio turnover rate(6)	8.52%	21.93%	2.97%
Short-term borrowings, end of period (000's)	\$ 12,300	\$ 12,700	\$ 11,300
Long-term debt obligations, end of period (000's)	\$ 20,000	\$ 20,000	\$ 20,000
Per common share amount of long-term debt obligations outstanding, end of period	\$ 2.88	\$ 2.88	\$ 2.90

## Edgar Filing: DR REDDYS LABORATORIES LTD - Form 6-K

Per common share amount of net assets, excluding long-term debt obligations, end of period	\$ 28.63	\$ 27.35	\$ 23.45
Asset coverage, per \$1,000 of principal amount of long-term debt obligations and short-term borrowings(8)	\$ 6,534	\$ 6,195	\$ 5,530
Asset coverage ratio of long-term debt obligations and short-term borrowings(8)	653%	619%	553%

- (1) Commencement of Operations.
- (2) Information presented relates to a share of common stock outstanding for the entire period.
- (3) The per common share data for the period from July 31, 2009 through November 30, 2009 do not reflect the change in estimate of investment income and return of capital. See Note 2C to the financial statements for further disclosure.
- (4) Not annualized. Total investment return is calculated assuming a purchase of common stock at the beginning of the period (or initial public offering price) and a sale at the closing price on the last day of the period reported (excluding brokerage commissions). The calculation also assumes reinvestment of distributions at actual prices pursuant to the Company's dividend reinvestment plan.
- (5) Not annualized. Total investment return is calculated assuming a purchase of common stock at the beginning of period (or initial public offering price) and a sale at net asset value on the last day of the period. The calculation also assumes reinvestment of distributions at actual prices pursuant to the Company's dividend reinvestment plan.
- (6) Annualized for periods less than one full year.
- (7) The Company accrued \$0, \$1,660 and \$0 for the period from December 1, 2010 to February 28, 2011, the year ended November 30, 2010, and the period from July 31, 2009 through November 30, 2009, respectively, for current foreign tax expense. Ratio is less than 0.01% for the year ended November 30, 2010.
- (8) Represents value of total assets less all liabilities and indebtedness not represented by long-term debt obligations and short-term borrowings at the end of the period divided by long-term debt obligations and short-term borrowings outstanding at the end of the period.

See accompanying Notes to Financial Statements.

10 Tortoise Power and Energy Infrastructure Fund, Inc.

---

---

---

Notes to Financial Statements (Unaudited)

February 28, 2011

1. Organization

Tortoise Power and Energy Infrastructure Fund, Inc. (the "Company") was organized as a Maryland corporation on July 5, 2007, and is a non-diversified, closed-end management investment company under the Investment Company Act of 1940, as amended (the "1940 Act"). The Company's primary investment objective is to provide a high level of current income, with a secondary objective of capital appreciation. The Company seeks to provide its stockholders with a vehicle to invest in a portfolio consisting primarily of securities issued by power and energy infrastructure companies. The Company commenced operations on July 31, 2009. The Company's stock is listed on the New York Stock Exchange under the symbol "TPZ."

2. Significant Accounting Policies

A. Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, recognition of distribution income and disclosure of contingent assets and liabilities at the date of the financial statements. Actual results could differ from those estimates.

B. Investment Valuation

The Company primarily owns securities that are listed on a securities exchange or over-the-counter market. The Company values those securities at their last sale price on that exchange or over-the-counter market on the valuation date. If the security is listed on more than one exchange, the Company uses the price from the exchange that it considers to be the principal exchange on which the security is traded. Securities listed on the NASDAQ will be valued at the NASDAQ Official Closing Price, which may not necessarily represent the last sale price. If there has been no sale on such exchange or over-the-counter market on such day, the security will be valued at the mean between the last bid price and last ask price on such day.

The Company may invest up to 15 percent of its total assets in restricted securities. Restricted securities are subject to statutory or contractual restrictions on their public resale, which may make it more difficult to obtain a valuation and may limit the Company's ability to dispose of them. Investments in private placement securities and other securities for which market quotations are not readily available will be valued in good faith by using fair value procedures approved by the Board of Directors. Such fair value procedures consider factors such as discounts to publicly traded issues, time until conversion date, securities with similar yields, quality, type of issue, coupon, duration and rating. If events occur that affect the value of the Company's portfolio securities before the net asset value has been calculated (a "significant event"), the portfolio securities so affected will generally be priced using fair value procedures.

An equity security of a publicly traded company acquired in a direct placement transaction may be subject to restrictions on resale that can affect the security's liquidity and fair value. Such securities that are convertible or otherwise will become freely tradable will be valued based on the market value of the freely tradable security less an applicable discount. Generally, the discount will initially be equal to the discount at which the Company purchased the securities. To the extent that such securities are convertible or otherwise become freely tradable within a time frame that may be reasonably determined, an amortization schedule may be used to determine the discount.

The Company generally values debt securities at prices based on market quotations for such securities, except those securities purchased with 60 days or less to maturity are valued on the basis of amortized cost, which approximates market value.

The Company generally values its interest rate swap contracts using industry-accepted models which discount the estimated future cash flows based on the stated terms of the interest rate swap agreement by using interest rates currently available in the market, or based on dealer quotations, if available.

C. Security Transactions and Investment Income

Security transactions are accounted for on the date the securities are purchased or sold (trade date). Realized gains and losses are reported on an identified cost basis. Interest income is recognized on the accrual basis, including amortization of premiums and accretion of discounts. Dividend and distribution income is recorded on the ex-dividend date. Distributions received from the Company's investments in master limited partnerships ("MLPs") generally are comprised of ordinary income, capital gains and return of capital from the MLPs. The Company allocates distributions between investment income and return of capital based on estimates made at the time such distributions are received. Such estimates are based on historical information available from each MLP and other industry sources. These estimates may subsequently be revised based on actual allocations received from MLPs after their tax reporting periods are concluded, as the actual character of these distributions is not known until after the fiscal year end of the Company.

For the period from December 1, 2010 through February 28, 2011, the Company estimated the allocation of investment income and return of capital for the distributions received from MLPs within the Statement of Operations. For this period, the Company has estimated approximately 10 percent as investment income and approximately 90 percent as return of capital.

#### D. Distributions to Stockholders

Distributions to common stockholders are recorded on the ex-dividend date. The Company intends to make monthly cash distributions of its investment company income to common stockholders. In addition, on an annual basis, the Company may distribute additional capital gains in the last fiscal quarter if necessary to meet minimum distribution requirements and thus avoid being subject to excise taxes. The amount of any distributions will be determined by the Board of Directors. Distributions to stockholders are recorded on the ex-dividend date. The character of distributions made during the year may differ from their ultimate characterization for federal income tax purposes. Distributions paid to stockholders in excess of investment company taxable income and net realized gains will be treated as return of capital to stockholders. For the year ended November 30, 2010, the Company's distributions were comprised of 87 percent ordinary income, 6 percent long-term capital gain and 7 percent return of capital. The tax character of distributions paid to common stockholders for the current year will be determined subsequent to November 30, 2011.

---

---

Notes to Financial Statements (Unaudited)

(Continued)

E. Federal Income Taxation

The Company qualifies as a regulated investment company (“RIC”) under the U.S. Internal Revenue Code of 1986, as amended (the “Code”). As a result, the Company generally will not be subject to U.S. federal income tax on income and gains that it distributes each taxable year to stockholders if it meets certain minimum distribution requirements. The Company is required to distribute substantially all of its income, in addition to other asset diversification requirements. The Company is subject to a 4 percent non-deductible U.S. federal excise tax on certain undistributed income unless the Company makes sufficient distributions to satisfy the excise tax avoidance requirement. The Company invests in MLPs, which generally are treated as partnerships for federal income tax purposes. As a limited partner in the MLPs, the Company reports its allocable share of the MLP’s taxable income in computing its own taxable income.

The Company has adopted financial reporting rules regarding recognition and measurement of tax positions taken or expected to be taken on a tax return. The Company has reviewed all open tax years and major jurisdictions and concluded that there is no impact on the Company’s net assets and no tax liability resulting from unrecognized tax benefits relating to uncertain income tax positions taken or expected to be taken on a tax return. All tax years since inception remain open to examination by federal and state tax authorities.

F. Offering and Debt Issuance Costs

Offering costs related to the issuance of common stock are charged to additional paid-in capital when the stock is issued. Debt issuance costs related to long-term debt obligations are capitalized and amortized over the period the debt is outstanding.

G. Derivative Financial Instruments

The Company uses derivative financial instruments (principally interest rate swap contracts) to manage interest rate risk. The Company has established policies and procedures for risk assessment and the approval, reporting and monitoring of derivative financial instrument activities. The Company does not hold or issue derivative financial instruments for speculative purposes. All derivative financial instruments are recorded at fair value with changes in fair value during the reporting period, and amounts accrued under the agreements, included as unrealized gains or losses in the Statement of Operations. Cash settlements under the terms of the interest rate swap agreements and termination of such agreements are recorded as realized gains or losses in the Statement of Operations.

H. Indemnifications

Under the Company’s organizational documents, its officers and directors are indemnified against certain liabilities arising out of the performance of their duties to the Company. In addition, in the normal course of business, the Company may enter into contracts that provide general indemnification to other parties. The Company’s maximum exposure under these arrangements is unknown, as this would involve future claims that may be made against the Company that have not yet occurred, and may not occur. However, the Company has not had prior claims or losses pursuant to these contracts and expects the risk of loss to be remote.

3. Concentration of Risk

Under normal circumstances, the Company intends to invest at least 80 percent of total assets (including assets obtained through potential leverage) in securities of companies that derive more than 50 percent of their revenue from power or energy operations and no more than 25 percent of the total assets in equity securities of MLPs as of the date of purchase. The Company will invest a minimum of 60 percent of total assets in fixed income securities, which may include up to 25 percent of its assets in non-investment grade rated fixed income securities. In determining application of these policies, the term “total assets” includes assets obtained through leverage. Companies that primarily invest in a particular sector may experience greater volatility than companies investing in a broad range of industry sectors. The Company may, for defensive purposes, temporarily invest all or a significant portion of its assets in investment grade securities, short-term debt securities and cash or cash equivalents. To the extent the Company uses this strategy, it may not achieve its investment objective.

4. Agreements

## Edgar Filing: DR REDDYS LABORATORIES LTD - Form 6-K

The Company has entered into an Investment Advisory Agreement with Tortoise Capital Advisors, L.L.C. (the "Adviser"). Under the terms of the agreement, the Company pays the Adviser a fee equal to an annual rate of 0.95 percent of the Company's average monthly total assets (including any assets attributable to leverage) minus accrued liabilities (other than debt entered into for purposes of leverage and the aggregate liquidation preference of outstanding preferred stock) ("Managed Assets"), in exchange for the investment advisory services provided. The Adviser has agreed to a fee waiver of 0.15 percent of average monthly Managed Assets for the period from July 31, 2009 through December 31, 2011, and a fee waiver of 0.10 percent of average monthly Managed Assets for the period from January 1, 2012 through December 31, 2012.

U.S. Bancorp Fund Services, LLC serves as the Company's administrator. The Company pays the administrator a monthly fee computed at an annual rate of 0.04 percent of the first \$1,000,000,000 of the Company's Managed Assets, 0.03 percent on the next \$1,000,000,000 of Managed Assets and 0.02 percent on the balance of the Company's Managed Assets.

Computershare Trust Company, N.A. serves as the Company's transfer agent and registrar and Computershare Inc. serves as the Company's dividend paying agent and agent for the automatic dividend reinvestment plan.

U.S. Bank, N.A. serves as the Company's custodian. The Company pays the custodian a monthly fee computed at an annual rate of 0.004 percent on the average daily market value of the Company's portfolio assets, subject to a minimum annual fee of \$4,800, plus portfolio transaction fees.

12 Tortoise Power and Energy Infrastructure Fund, Inc.

---

## Notes to Financial Statements (Unaudited)

(Continued)

## 5. Income Taxes

It is the Company's intention to continue to qualify as a regulated investment company under Subchapter M of the Internal Revenue Code and distribute all of its taxable income. Accordingly, no provision for federal income taxes is required in the financial statements.

The amount and character of income and capital gain distributions to be paid, if any, are determined in accordance with federal income tax regulations, which may differ from U.S. generally accepted accounting principles. These differences are primarily due to differences in the timing of recognition of gains or losses on investments. Permanent book and tax basis differences, if any, may result in reclassifications to undistributed net investment income (loss), accumulated net realized gain (loss) and additional paid-in capital.

As of November, 2010, the components of accumulated earnings on a tax basis were as follows:

Unrealized appreciation	\$ 39,732,441
Other temporary differences	(32,877)
Accumulated earnings	\$ 39,699,564

As of February 28, 2011, the aggregate cost of securities for federal income tax purposes was \$158,312,624. The aggregate gross unrealized appreciation for all securities in which there was an excess of value over tax cost was \$51,416,231, the aggregate gross unrealized depreciation for all securities in which there was an excess of tax cost over value was \$0 and the net unrealized appreciation was \$51,416,231.

## 6. Fair Value of Financial Instruments

Various inputs are used in determining the value of the Company's investments. These inputs are summarized in the three broad levels listed below:

Level 1 —quoted prices in active markets for identical investments

Level 2 —other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.)

Level 3 —significant unobservable inputs (including the Company's own assumptions in determining the fair value of investments)

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

The following table provides the fair value measurements of applicable Company assets and liabilities by level within the fair value hierarchy as of February 28, 2011. These assets and liabilities are measured on a recurring basis.

Description	Fair Value at			
	February 28, 2011	Level 1	Level 2	Level 3
<b>Assets</b>				
<b>Debt Securities:</b>				
Corporate Bonds(a)	\$ 116,379,092	\$ 5,279,550	\$ 111,099,542	\$ —
Total Debt Securities	116,379,092	5,279,550	111,099,542	—
<b>Equity Securities:</b>				
Master Limited Partnerships and Related Companies(a)	93,312,597	93,312,597	—	—
Total Equity Securities	93,312,597	93,312,597	—	—
<b>Other:</b>				
Short-Term Investment(b)	37,166	37,166	—	—

Edgar Filing: DR REDDYS LABORATORIES LTD - Form 6-K

Total Other	37,166	37,166	—	—
Total Assets	\$ 209,728,855	\$ 98,629,313	\$ 111,099,542	\$ —
Liabilities				
Interest Rate Swap Contracts	\$ 683,459	\$ —	\$ 683,459	\$ —
Total	\$ 209,045,396	\$ 98,629,313	\$ 110,416,083	\$ —

(a) All other industry classifications are identified in the Schedule of Investments.

(b) Short-term investment is a sweep investment for cash balances in the Company at February 28, 2011.

Valuation Techniques

In general, and where applicable, the Company uses readily available market quotations based upon the last updated sales price from the principal market to determine fair value. This pricing methodology applies to the Company's Level 1 investments.

Some debt securities are fair valued using a market value obtained from an approved pricing service which utilizes a pricing matrix based upon yield data for securities with similar characteristics or from a direct written broker-dealer quotation from a dealer who has made a market in the security. This pricing methodology applies to the Company's Level 2 assets.

Interest rate swap contracts are valued by using industry-accepted models which discount the estimated future cash flows based on a forward rate curve and the stated terms of the interest rate swap agreement by using interest rates currently available in the market, or based on dealer quotations, if available, which applies to the Company's Level 2 liabilities.

The Company utilizes the beginning of reporting period method for determining transfers between levels. There were no transfers between levels for the period from December 1, 2010 through February 28, 2011.



## Notes to Financial Statements (Unaudited)

(Continued)

## 7. Restricted Securities

Certain of the Company's investments are restricted and are valued as determined in accordance with procedures established by the Board of Directors, as more fully described in Note 2. The table below shows the principal amount, acquisition date(s), acquisition cost, fair value and the percent of net assets which the securities comprise at February 28, 2011.

Investment Security	Principal Amount	Acquisition Date(s)	Acquisition Cost	Fair Value	Fair Value as Percent of Net Assets
DCP Midstream LLC, 9.750%, 03/15/2019	\$ 4,000,000	08/07/09- 08/27/09	\$ 4,769,350	\$ 5,178,344	2.9%
El Paso Corp., 6.500%, 09/15/2020	4,000,000	09/24/10	4,000,000	4,258,784	2.4
Enogex LLC, 6.250%, 03/15/2020	4,000,000	02/26/10- 04/22/10	4,118,593	4,295,432	2.4
Florida Gas Transmission Co., LLC, 5.450%, 07/15/2020	1,500,000	07/08/10- 01/04/11	1,551,220	1,571,618	0.9
IPALCO Enterprises, Inc., 7.250%, 04/01/2016	4,000,000	11/03/09- 01/04/11	4,165,000	4,340,000	2.4
Midcontinent Express Pipelines, LLC, 6.700%, 09/15/2019	6,000,000	09/09/09- 03/02/10	6,055,570	6,631,176	3.7
NGPL PipeCo, LLC, 7.119%, 12/15/2017	4,000,000	07/29/10- 09/28/10	4,280,000	4,497,776	2.5
North American Energy Alliance LLC, 10.875%, 06/01/2016	2,800,000	09/24/09- 10/08/09	2,895,000	3,164,000	1.8
Source Gas, LLC, 5.900%, 04/01/2017	5,770,000	04/21/10	5,544,521	5,701,210	3.2
Southern Star Central Gas Pipeline, Inc., 6.000%, 06/01/2016	2,000,000	08/24/09	1,970,000	2,161,278	1.2
			\$ 39,349,254	\$ 41,799,618	23.4%

## 8. Investment Transactions

For the period from December 1, 2010 through February 28, 2011, the Company purchased (at cost) and sold securities (proceeds received) in the amount of \$4,279,590 and \$5,293,689 (excluding short-term debt securities), respectively.

## 9. Long-Term Debt Obligations

The Company has \$20,000,000 aggregate principal amount of Series A private senior notes (the "Notes") outstanding. Holders of the Notes are entitled to receive quarterly cash interest payments at an annual rate that resets each quarter based on the 3-month LIBOR plus 1.87 percent. The Notes are not listed on any exchange or automated quotation system.

The Notes are unsecured obligations of the Company and, upon liquidation, dissolution or winding up of the Company, will rank: (1) senior to all of the Company's outstanding preferred shares (if any); (2) senior to all of the Company's outstanding common shares; (3) on parity with any unsecured creditors of the Company and any unsecured senior securities representing indebtedness of the Company and (4) junior to any secured

## Edgar Filing: DR REDDYS LABORATORIES LTD - Form 6-K

creditors of the Company.

The Notes are redeemable in certain circumstances at the option of the Company. The Notes are also subject to a mandatory redemption if the Company fails to meet asset coverage ratios required under the 1940 Act or the rating agency guidelines if such failure is not waived or cured. At February 28, 2011, the Company was in compliance with asset coverage covenants and basic maintenance covenants for its senior notes.

At February 28, 2011, fair value of the Series A Notes approximates the carrying amount because the interest rate fluctuates with changes in interest rates available in the current market. The following table shows the maturity date, notional/carrying amount, current rate as of February 28, 2011, and the weighted-average rate for the period from December 1, 2010 through February 28, 2011.

Series	Maturity Date	Notional/Carrying Amount	Current Rate	Weighted- Average Rate
Series A	November 6, 2014	\$20,000,000	2.18%	2.16%

14 Tortoise Power and Energy Infrastructure Fund, Inc.

---

## Notes to Financial Statements (Unaudited)

(Continued)

## 10. Interest Rate Swap Contracts

The Company has entered into interest rate swap contracts in an attempt to protect itself from increasing interest expense on its leverage resulting from increasing short-term interest rates. A decline in interest rates may result in a decline in the value of the swap contracts, which may result in a decline in the net assets of the Company. In addition, if the counterparty to the interest rate swap contracts defaults, the Company would not be able to use the anticipated receipts under the swap contracts to offset the interest payments on the Company's leverage. At the time the interest rate swap contracts reach their scheduled termination, there is a risk that the Company would not be able to obtain a replacement transaction, or that the terms of the replacement would not be as favorable as on the expiring transaction. In addition, if the Company is required to terminate any swap contract early due to the Company failing to maintain a required 300 percent asset coverage of the liquidation value of the outstanding senior notes or if the Company loses its credit rating on its senior notes, then the Company could be required to make a termination payment, in addition to redeeming all or some of the senior notes. Details of the interest rate swap contracts outstanding as of February 28, 2011, are as follows:

Counterparty	Maturity Date	Notional Amount	Fixed Rate	Floating Rate	Asset
			Paid by the Company	Received by the Company	(Liability) Derivatives
Wells Fargo Bank, N.A.	11/06/2011	\$ 6,000,000	1.12%	1-month U.S. Dollar LIBOR	\$ (37,531)
Wells Fargo Bank, N.A.	11/06/2012	5,000,000	1.81%	3-month U.S. Dollar LIBOR	(99,874)
Wells Fargo Bank, N.A.	11/06/2012	1,000,000	1.73%	1-month U.S. Dollar LIBOR	(19,688)
Wells Fargo Bank, N.A.	11/06/2014	15,000,000	2.66%	3-month U.S. Dollar LIBOR	(526,366)
		\$ 27,000,000			\$ (683,459)

The Company is exposed to credit risk on the interest rate swap contracts if the counterparty should fail to perform under the terms of the interest rate swap contracts. The amount of credit risk is limited to the net appreciation of the interest rate swap contracts, if any, as no collateral is pledged by the counterparty.

The change in unrealized appreciation of interest rate swap contracts in the amount of \$301,565 is included in the Statement of Operations for the period ended February 28, 2011. Cash settlement payments under the terms of the interest rate swap contracts in the amount of \$126,052 are recorded as realized losses for the period ended February 28, 2011. The total notional amount of all open swap agreements at February 28, 2011 is indicative of the volume of this derivative type for the period ended February 28, 2011.

## 11. Credit Facility

On September 14, 2010, the Company entered into an amendment to its credit facility that extends the credit facility through September 14, 2011. U.S. Bank, N.A. serves as a lender and the leading syndicate agent on behalf of other lenders participating in the credit facility. The terms of the amendment provide for an unsecured revolving credit facility of \$18,000,000. During the extension, outstanding balances generally will accrue interest at a variable annual rate equal to one-month LIBOR plus 1.25 percent and unused portions of the credit facility will accrue a non-usage fee equal to an annual rate of 0.20 percent.

The average principal balance and interest rate for the period during which the credit facility was utilized during the period ended February 28, 2011 was approximately \$11,900,000 and 1.51 percent, respectively. At February 28, 2011, the principal balance outstanding was \$12,300,000 at an interest rate of 1.51 percent.

Under the terms of the credit facility, the Company must maintain asset coverage required under the 1940 Act. If the Company fails to maintain the required coverage, it may be required to repay a portion of an outstanding balance until the coverage requirement has been met. At February 28, 2011, the Company was in compliance with the terms of the credit facility.

## 12. Common Stock

## Edgar Filing: DR REDDYS LABORATORIES LTD - Form 6-K

The Company has 100,000,000 shares of capital stock authorized and 6,940,986 shares outstanding at February 28, 2011 and November 30, 2010.

### 13. Subsequent Events

On March 31, 2011, the Company paid a distribution in the amount of \$0.125 per common share, for a total of \$867,623. Of this total, the dividend reinvestment amounted to \$143,485.

The Company has performed an evaluation of subsequent events through the date the financial statements were issued and has determined that no additional items require recognition or disclosure.

2011 1st Quarter Report 15

---

---

---

## Additional Information (Unaudited)

### Director and Officer Compensation

The Company does not compensate any of its directors who are “interested persons,” as defined in Section 2(a)(19) of the 1940 Act, nor any of its officers. For the period ended February 28, 2011, the aggregate compensation paid by the Company to the independent directors was \$20,250. The Company did not pay any special compensation to any of its directors or officers.

### Forward-Looking Statements

This report contains “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934. By their nature, all forward-looking statements involve risks and uncertainties, and actual results could differ materially from those contemplated by the forward-looking statements. Several factors that could materially affect the Company’s actual results are the performance of the portfolio of investments held by it, the conditions in the U.S. and international financial, petroleum and other markets, the price at which shares of the Company will trade in the public markets and other factors discussed in filings with the SEC.

### Proxy Voting Policies

A description of the policies and procedures that the Company uses to determine how to vote proxies relating to portfolio securities owned by the Company and information regarding how the Company voted proxies relating to the portfolio of securities during the 12-month period ended June 30, 2010 are available to stockholders (i) without charge, upon request by calling the Company at (913) 981-1020 or toll-free at (866) 362-9331 and on the Company’s Web site at [www.tortoiseadvisors.com](http://www.tortoiseadvisors.com); and (ii) on the SEC’s Web site at [www.sec.gov](http://www.sec.gov).

### Form N-Q

The Company files its complete schedule of portfolio holdings for the first and third quarters of each fiscal year with the SEC on Form N-Q. The Company’s Form N-Q is available without charge upon request by calling the Company at (866) 362-9331 or by visiting the SEC’s Web site at [www.sec.gov](http://www.sec.gov). In addition, you may review and copy the Company’s Form N-Q at the SEC’s Public Reference Room in Washington D.C. You may obtain information on the operation of the Public Reference Room by calling (800) SEC-0330.

The Company’s Form N-Qs are also available on the Company’s Web site at [www.tortoiseadvisors.com](http://www.tortoiseadvisors.com).

### Statement of Additional Information

The Statement of Additional Information (“SAI”) includes additional information about the Company’s directors and is available upon request without charge by calling the Company at (866) 362-9331 or by visiting the SEC’s Web site at [www.sec.gov](http://www.sec.gov).

### Certifications

The Company’s Chief Executive Officer has submitted to the New York Stock Exchange the annual certification as required by Section 303A.12(a) of the NYSE Listed Company Manual.

The Company has filed with the SEC, as an exhibit to its most recently filed Form N-CSR, the certification of its Chief Executive Officer and Chief Financial Officer required by Section 302 of the Sarbanes-Oxley Act.

### Privacy Policy

In order to conduct its business, the Company collects and maintains certain nonpublic personal information about its stockholders of record with respect to their transactions in shares of the Company’s securities. This information includes the stockholder’s address, tax identification or Social Security number, share balances, and distribution elections. We do not collect or maintain personal information about stockholders whose share balances of our securities are held in “street name” by a financial institution such as a bank or broker.

## Edgar Filing: DR REDDYS LABORATORIES LTD - Form 6-K

We do not disclose any nonpublic personal information about you, the Company's other stockholders or the Company's former stockholders to third parties unless necessary to process a transaction, service an account, or as otherwise permitted by law.

To protect your personal information internally, we restrict access to nonpublic personal information about the Company's stockholders to those employees who need to know that information to provide services to our stockholders. We also maintain certain other safeguards to protect your nonpublic personal information.

16 Tortoise Power and Energy Infrastructure Fund, Inc.

---

Office of the Company  
and of the Investment Adviser  
Tortoise Capital Advisors, L.L.C.  
11550 Ash Street, Suite 300  
Leawood, Kan. 66211  
(913) 981-1020  
(913) 981-1021 (fax)  
www.tortoiseadvisors.com

Managing Directors of  
Tortoise Capital Advisors, L.L.C.  
H. Kevin Birzer  
Zachary A. Hamel  
Kenneth P. Malvey  
Terry Matlack  
David J. Schulte

Board of Directors of Tortoise Power  
and Energy Infrastructure Fund, Inc.

H. Kevin Birzer, Chairman  
Tortoise Capital Advisors

Conrad S. Ciccotello  
Independent

John R. Graham  
Independent

Charles E. Heath  
Independent

ADMINISTRATOR  
U.S. Bancorp Fund Services, LLC  
615 East Michigan St.  
Milwaukee, Wis. 53202

CUSTODIAN  
U.S. Bank, N.A.  
1555 North Rivercenter Drive, Suite 302  
Milwaukee, Wis. 53212

TRANSFER, DIVIDEND DISBURSING  
AND DIVIDEND REINVESTMENT PLAN AGENT  
Computershare Trust Company, N.A. / Computershare Inc.  
P.O. Box 43078  
Providence, R.I. 02940-3078  
(800) 426-5523  
www.computershare.com

LEGAL COUNSEL  
Husch Blackwell LLP  
4801 Main St.  
Kansas City, Mo. 64112

INVESTOR RELATIONS  
(866) 362-9331  
info@tortoiseadvisors.com

STOCK SYMBOL  
Listed NYSE Symbol: TPZ

This report is for stockholder information. This is not a prospectus intended for use in the purchase or sale of fund shares. Past performance is no guarantee of future results and your investment may be worth more or less at the time you sell.

Tortoise Capital Advisors' Public Investment Companies

Name	Ticker/ Inception Date	Primary Target Investments	Investor Suitability	Total Assets as of 3/31/11 (\$ in millions)
Tortoise Power and Energy Infrastructure Fund, Inc.	TPZ July 2009	U.S. Power and Energy Investment Grade Debt and Dividend-Paying Equity Securities	Retirement Accounts Pension Plans Taxable Accounts	\$209
Tortoise Energy Infrastructure Corp.	TYG Feb. 2004	U.S. Energy Infrastructure	Retirement Accounts Pension Plans Taxable Accounts	\$1,561
Tortoise Energy Capital Corp.	TYY May 2005	U.S. Energy Infrastructure	Retirement Accounts Pension Plans	\$816

Edgar Filing: DR REDDYS LABORATORIES LTD - Form 6-K

			Taxable Accounts	
Tortoise North American Energy Corp.	TYN Oct. 2005	U.S. Energy Infrastructure	Retirement Accounts Pension Plans Taxable Accounts	\$211
Tortoise MLP Fund, Inc.	NTG July 2010	U.S. Energy Infrastructure Natural Gas Energy Infrastructure Emphasis	Retirement Accounts Pension Plans Taxable Accounts	\$1,641
Tortoise Capital Resources Corp.	TTO Dec. 2005 (Feb. 2007 – IPO)	U.S. Energy Infrastructure Private and Micro Cap Public Companies	Retirement Accounts Pension Plans Taxable Accounts	\$97 (as of 2/28/11)

---



